search
Back to results

Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas

Primary Purpose

Larynx Disease

Status
Withdrawn
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Esomeprazole
Sponsored by
Vanderbilt University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Larynx Disease

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients with vocal cord granulomas

Exclusion Criteria:

  • Age < 18
  • Pregnancy
  • Use of proton pump inhibitor (PPI) within the last 30 days

Sites / Locations

  • Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

A 1

A2

Arm Description

Arm I: placebo group receives BID placebo

subjects receive active drug, esomeprazole 40 mg BID

Outcomes

Primary Outcome Measures

• Primary outcome: Vocal cord granuloma improvement +/- resolution Outcome categories-subjectively assessed at laryngoscopy (current practice)

Secondary Outcome Measures

Symptom improvement +/- resolution

Full Information

First Posted
December 3, 2007
Last Updated
September 4, 2013
Sponsor
Vanderbilt University
search

1. Study Identification

Unique Protocol Identification Number
NCT00567658
Brief Title
Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas
Official Title
Effect of Aggressive Acid Suppression With Esomeprazole on Vocal Cord Granulomas: Randomized Placebo-Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Withdrawn
Why Stopped
The decision of terminate the study was reached due to difficulties surrounding recruitment and enrollment of subjects since the inception of the study.
Study Start Date
February 2008 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
January 2010 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this research study is to measure the effects of the drug, esomeprazole 40 mg (Nexium) or placebo (inactive drug) on vocal cord granulomas.
Detailed Description
Vocal cord granulomas (VCG) are common structural lesions of vocal cords attributed to vocal abuse / misuse and recently to gastroesophageal reflux. Vocal process granulomas are reactive/reparative process, in which an intact or ulcerated squamous epithelium is underlaid by granulation tissue or fibrosis (4, 5). Ulualp et al (6) have reported a higher prevalence of pharyngeal acid reflux (PAR) events in patients with vocal cord lesions. In a case control study they showed that the prevalence of pharyngeal reflux, documented with 3 site pharyngoesophageal pH monitoring, is higher among patients with posterior laryngitis and vocal cord lesions than control (78% vs. 21%). Most recently our cohort trial in over 80 patients with laryngeal findings suggestive of GERD suggested that vocal cord abnormalities such as granulomas may be more specific sign of GERD than any other (7). Thus, there is reasonable scientific intrigue regarding this laryngeal finding and the causal role from gastroesophagopharyngeal acid reflux requiring better studies. However, no study has evaluated the potential causal association between GERD and VCGs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Larynx Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A 1
Arm Type
Placebo Comparator
Arm Description
Arm I: placebo group receives BID placebo
Arm Title
A2
Arm Type
Experimental
Arm Description
subjects receive active drug, esomeprazole 40 mg BID
Intervention Type
Drug
Intervention Name(s)
Esomeprazole
Intervention Description
Esomeprazole or Nexium 40 mg BID is given for four months.
Primary Outcome Measure Information:
Title
• Primary outcome: Vocal cord granuloma improvement +/- resolution Outcome categories-subjectively assessed at laryngoscopy (current practice)
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Symptom improvement +/- resolution
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with vocal cord granulomas Exclusion Criteria: Age < 18 Pregnancy Use of proton pump inhibitor (PPI) within the last 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael F Vaezi, MD, PhD, MS epi
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas

We'll reach out to this number within 24 hrs